The Peptide Antibiotics Market size was valued at USD 5.09 billion in 2024 and is expected to reach USD 7.57 billion by 2032, growing at a CAGR of 5.14% over the forecast period of 2025-2032.
To Get more information on Peptide Antibiotics Market - Request Free Sample Report
The peptide antibiotics market is growing steadily with the increasing antimicrobial resistance (AMR) and the pressing demand for new therapeutic agents. Peptide antibiotics possess broad-spectrum activity and less resistance development, which makes them promising alternatives to conventional antibiotics. Growing R&D spending, positive regulatory support, and improvements in peptide synthesis technologies are further driving the market.
The U.S. peptide antibiotics market size was valued at USD 1.94 billion in 2024 and is expected to reach USD 2.84 billion by 2032, growing at a CAGR of 4.92% over the forecast period of 2025-2032.
In July 2024, the CDC published its report on antimicrobial resistance threats in the United States, 2021–2022, wherein it found six categories of hospital-onset bacterial antimicrobial-resistant infections grew together by a total of 20% during the COVID-19 pandemic years versus before the pandemic, with an all-time high in 2021 and continued high levels in 2022. The report also reported an almost five-fold increase in reported clinical cases of Candida auris, a yeast resistant to drugs that spread in healthcare facilities and can lead to serious illness, from 2019 through 2022.
The U.S. leads the North American peptide antibiotics market due to its advanced pharmaceutical R&D centers, strong regulatory system, and significant investments in combating antimicrobial resistance. Its well-established healthcare infrastructure and grants for the development of new antibiotics also contribute to this leadership.
Drivers
Emerging Antimicrobial Resistance (AMR) Driving the Market Growth
Antimicrobial resistance is among the most critical health threats worldwide, according to the CDC. In the U.S., more than 2.8 million antimicrobial-resistant infections occur each year since bacteria continue to develop resistance against conventional antibiotics, making many therapies useless. This has dictated a requirement for novel therapies able to function powerfully against recalcitrant microbes. Antibiotics that target peptides represent a perfect answer in that they possess unique modes of action, ranging from the destabilization of bacterial membranes or even the inhibition of specific proteins, which complicates resistance in bacteria. As healthcare systems struggle with increasing challenges in treating resistant infections, the need for peptide antibiotics keeps growing, making them a key element in the future peptide antibiotics market growth.
Increasing Prevalence of Hospital-Acquired Infections (HAIs) Propelling the Market Growth
Hospital-acquired infections, such as bloodstream infections, pneumonia, and surgical site infections, are of serious concern in clinical practice, especially in intensive care units. These infections are usually caused by resistant bacteria and need to be treated with effective antibiotics. Peptide antibiotics, particularly in injectable forms, are usually employed in hospitals to treat such life-threatening infections because they exhibit broad-spectrum activity and a rapid onset of action. The rising rate of surgical procedures, longer hospital stays, and immunocompromised hosts have all led to an increase in HAIs, hence the need for reliable and innovative antimicrobial agents, such as antibiotic resistance and peptides.
As reported by the Centers for Disease Control and Prevention (CDC), on average, 1 out of every 31 patients who are hospitalized each day will have at least one healthcare-associated infection.
The CDC estimates that almost 5% of all hospitalizations result in a healthcare-associated infection and cause approximately 722,000 infections and 75,000 deaths each year in the U.S.
Restraint
High Production Costs and Sophisticated Manufacturing Restricting the Market Growth
Peptide antibiotics require advanced synthesis protocols, which are complicated and technology-intensive. This is coupled with high production costs and the ability to produce in large quantities, particularly among small and medium-scale manufacturers. The resulting high cost reflects on prices and reimbursement rates in price-sensitive markets.
The world faces a severe access and pipeline crisis of antibiotics, with woefully insufficient research and development pipeline to meet increasing antimicrobial resistance. The immediate need is for greater efforts to ensure equitable access to new and existing vaccines, diagnostics, and medicines. Apart from the cost of disability and death, AMR has a substantial economic cost.
For Instance, Antimicrobial resistance, the World Bank estimates, could lead to an additional USD 1 trillion in healthcare spending by 2050 and global GDP losses between USD 1 trillion and USD 3.4 trillion annually by 2030.
By Product
The non-ribosomal synthesized peptide antibiotics segment dominated the peptide antibiotics market share with 72.16% in 2024 because of their extensive activity and increased stability compared to ribosomally synthesized peptides. Non-ribosomal peptides are produced with a modular enzyme system, which enables the production of highly diverse, powerful antibiotics with fewer problems related to resistance. This is especially effective against multidrug-resistant pathogens, which are increasingly becoming a threat across the globe. Their capacity to act against a broad spectrum of infections, such as skin infections and hospital-acquired infections, has helped them dominate the market.
The ribosomally synthesized peptide antibiotics segment is expected to exhibit the fastest growth during the forecast period. These peptides are produced by the ribosome and are typically less complex and cheaper to manufacture than non-ribosomal peptides. Advances in peptide synthesis technologies and increasing research on their antimicrobial activity are driving their strong growth. The increasing prevalence of antimicrobial resistance (AMR) is also fueling the quest for ribosomal peptides as effective and affordable alternatives to traditional antibiotics, which is driving growth in this segment.
By Disease
The skin infection segment led the peptide antibiotics market with a 36.22% share in 2024 due to the vast number of bacterial skin infections, including impetigo and cellulitis, that require effective antimicrobial therapies. Peptide antibiotics, particularly non-ribosomal synthesis, have shown strong efficacy in killing resistant strains like MRSA (methicillin-resistant Staphylococcus aureus), which mostly cause skin infections. Also, the increasing realization regarding the shortcomings of conventional antibiotics and the rising rate of hospital-acquired infections (HAIs) related to the skin added to the dominance of this segment.
The bloodstream infections (BSI) segment is anticipated to exhibit the highest growth during the forecast period, with a 5.77% CAGR, owing to the rising number of patients with bloodstream infections due to multidrug-resistant bacteria. Bloodstream infections, such as sepsis, need quick and effective treatments, and peptide antibiotics have shown great promise in fighting these life-threatening infections.
By Route of Administration
The injectable segment dominated the peptide antibiotics market with a 44.18% market share in 2024 because injectable products provide more efficacy and quicker therapeutic response, particularly in severe infections. Injectable peptide antibiotics are also extensively used in hospitals to treat systemic and serious infections, such as bloodstream infection and hospital-acquired infection. The products ensure that the medication enters the body through the blood rapidly, allowing a faster response than oral antibiotics.
The oral segment is expected to register the highest growth during the forecast period since the need for less convenient, cost-effective, and patient-friendly solutions increases. Oral peptide antibiotics are easy to administer and can be used for outpatient or self-treatment, making them highly sought after by patients as well as medical professionals. Advancements in oral delivery technologies that improve the stability and bioavailability of the peptide antibiotics are driving growth in this segment.
By Distribution Channel
The hospital pharmacies segment led the peptide antibiotics market with 42.13% due to the major role played by hospitals in the treatment of severe and complex infections. Peptide antibiotics are typically prescribed for severe, multidrug-resistant infections, which are typically treated in hospital settings, particularly for hospital-acquired infections (HAIs) or bloodstream infection patients. Hospitals possess the requisite infrastructure in the form of trained healthcare personnel and the capability to administer intravenous or injectable preparations of antibiotics, which makes hospital pharmacies the first line of distribution for these specialized drugs.
The online pharmacies segment is anticipated to experience the fastest growth during the forecast period due to the increasing use of the e-commerce business model and customer preference for handy home delivery of drugs. Increasing awareness of peptide antibiotics and the requirement for alternative drug therapies against infection-resistant strains results in online pharmacies being a relatively more convenient proposition for patients in areas with inferior healthcare infrastructure.
Regional Analysis
North America dominated the peptide antibiotics market in 2024 with a share of 42.23% because of its well-developed healthcare infrastructure, high concentration of top drug companies, and the highest R&D investments in antibiotics. The region has supportive government programs and investments directed towards fighting antimicrobial resistance (AMR) and is supplemented by institutions such as the CDC and BARDA, promoting the release of new peptide therapeutics. Also, intense awareness among doctors and healthcare workers and an entrenched regulatory structure help new antibiotics reach the market speedily and come to commercial scale rapidly, enhancing the peptide antibiotics market analysis.
For instance, in March 2022, the UN General Assembly adopted resolution A/RES/76/257, calling for a second High-level Meeting on Antimicrobial Resistance (AMR), held in 2024 with support from the Quadripartite Organizations and the Global Leaders Group. The Permanent Representatives of Barbados and Malta were appointed as co-facilitators in October 2023. The meeting aimed to drive ambitious commitments across human, animal, agri-food, and environmental sectors.
The Asia Pacific is the fastest-growing region in the peptide antibiotics market, with a 6.10% CAGR over the forecast period due to growing infectious disease burdens and mounting rates of AMR in countries such as China and India. The region is seeing increasing access to healthcare, high urbanization rates, and increased investments in pharma R&D. Further, favorable government initiatives and a high rise in generic and biosimilar manufacturing facilities are driving peptide antibiotic development and adoption.
Europe is the most prominent region in the peptide antibiotics market with a strong pharmaceutical base, high R&D spending, and active antimicrobial resistance efforts. Germany and France are leaders in innovation and take-up, supported by supportive regulation and healthcare policies.
Germany leads the peptide antibiotics market in Europe with its superior pharma infrastructure, high R&D investment, and anti-antimicrobial resistance (AMR) regulatory pushes. The nation has experienced a rapid rise in bacterial infections, such as skin and blood infections, increasing the need for effective treatments through peptides. Government policies, including favorable reimbursement schemes and funding initiatives, have also promoted the growth and uptake of peptide antibiotics market trends.
Latin America is experiencing moderate peptide antibiotics market growth due to increasing consciousness about antimicrobial resistance, increasing investments in the healthcare sector, and gradual construction of pharmaceutical infrastructure in countries such as Brazil and Mexico. But economic imbalances, shortages of healthcare in rural regions, and uneven regulatory environments are slowing the rate of market growth.
In the Middle East & Africa (MEA), the region is witnessing steady growth driven by improved healthcare infrastructure, particularly in South Africa and Saudi Arabia, and a growing focus on addressing resistant infections. Although non-ribosomal synthesized peptide antibiotics are also picking up pace in the region, economic constraints and healthcare disparities continue to be dampening factors to their large-scale adoption.
Get Customized Report as per Your Business Requirement - Enquiry Now
Key Market Players
Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bachem Holding AG, Sandoz, Ipsen S.A., Merrion Pharmaceuticals, Taiwan Liposome Company, PolyPeptide Group, Melinta Therapeutics, and other players.
Recent Developments
In April 2025, Pfizer Inc. announced that it is ending development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist currently in development for treating chronic weight.
In February 2025, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech announced the U.S. launch of SELARSDI (ustekinumab-aekn) injection. This biosimilar to Stelara (ustekinumab) is indicated to treat psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, plaque psoriasis in children, and psoriatic arthritis.
In February 2025, The Novo Nordisk Foundation launched its Catalyst Grants, which were first launched in 2024, to speed up innovation and speedy testing of novel ideas in three areas of focus: antimicrobial resistance (AMR), invasive pathogenic fungi, and harnessing innate immunity against airborne viral infections.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 5.09 Billion |
| Market Size by 2032 | USD 7.57 Billion |
| CAGR | CAGR of 5.14% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | •By Product (Ribosomally Synthesized Peptide Antibiotics, Non-ribosomal Synthesized Peptide Antibiotics) •By Disease (Skin Infection, HABP/VABP, Blood Stream Infections, Others) •By Route of Administration (Oral, Injectable, Topical, Others) •By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Thermo Fisher Scientific, Agilent Technologies, Shimadzu Corporation, Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bachem Holding AG, Sandoz, Ipsen S.A., Merrion Pharmaceuticals, Taiwan Liposome Company, PolyPeptide Group, Melinta Therapeutics, and other players. |
Ans: The Peptide Antibiotics Market is expected to grow at a CAGR of 5.14% from 2025-2032.
Ans: The Peptide Antibiotics Market was USD 5.09 billion in 2024 and is expected to reach USD 7.57 billion by 2032.
Ans: Emerging Antimicrobial Resistance (AMR) Driving the Market Growth.
Ans: The “Skin Infection” segment dominated the Peptide Antibiotics Market.
Ans: North America dominated the Peptide Antibiotics Market in 2024.
Table Of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Infection Incidence and Prevalence, by Type (2024)
5.2 Antibiotic Resistance Trends (2020–2024), by Region
5.3 Clinical Trial Pipeline and Approvals (2020–2025)
5.4 R&D Investment in Antimicrobial Peptides (2020–2024)
5.5 Healthcare Spending on Antimicrobial Treatments (2024), by Region
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Peptide Antibiotics Market Segmentation By Product
7.1 Chapter Overview
7.2 Ribosomally Synthesized Peptide Antibiotics
7.2.1 Ribosomally Synthesized Peptide Antibiotics Market Trends Analysis (2020-2032)
7.2.2 Ribosomally Synthesized Peptide Antibiotics Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Non-ribosomal Synthesized Peptide Antibiotics
7.3.1 Non-ribosomal Synthesized Peptide Antibiotics Market Trends Analysis (2020-2032)
7.3.2 Non-ribosomal Synthesized Peptide Antibiotics Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Peptide Antibiotics Market Segmentation By Disease
8.1 Chapter Overview
8.2 Skin Infection
8.2.1 Skin Infection Market Trends Analysis (2020-2032)
8.2.2 Skin Infection Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 HABP/VABP
8.3.1 HABP/VABP Market Trends Analysis (2020-2032)
8.3.2 HABP/VABP Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Blood Stream Infections
8.4.1 Blood Stream Infections Market Trends Analysis (2020-2032)
8.4.2 Blood Stream Infections Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Others
8.5.1 Others Market Trends Analysis (2020-2032)
8.5.2 Others Market Size Estimates and Forecasts To 2032 (USD Billion)
9. Peptide Antibiotics Market Segmentation By Route of Administration
9.1 Chapter Overview
9.2 Oral
9.2.1 Oral Market Trends Analysis (2020-2032)
9.2.2 Oral Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Injectable
9.3.1 Injectable Market Trends Analysis (2020-2032)
9.3.2 Injectable Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Topical
9.4.1 Topical Market Trends Analysis (2020-2032)
9.4.2 Topical Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Others
9.5.1 Others Market Trends Analysis (2020-2032)
9.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Peptide Antibiotics Market Segmentation By Distribution Channel
10.1 Chapter Overview
10.2 Hospital Pharmacies
10.2.1 Hospital Pharmacies Market Trends Analysis (2020-2032)
10.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10.3 Retail Pharmacies
10.3.1 Retail Pharmacies Market Trend Analysis (2020-2032)
10.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10.4 Online Pharmacies
10.4.1 Online Pharmacies Market Trends Analysis (2020-2032)
10.4.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
11. Regional Analysis
11.1 Chapter Overview
11.2 North America
11.2.1 Trend Analysis
11.2.2 North America Peptide Antibiotics Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.2.3 North America Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.2.4 North America Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.2.5 North America Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.2.6 North America Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.2.7 USA
11.2.7.1 USA Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.2.7.2 USA Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.2.7.3 USA Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.2.7.4 USA Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.2.8 Canada
11.2.8.1 Canada Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.2.8.2 Canada Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.2.8.3 Canada Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.2.8.4 Canada Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.2.9 Mexico
11.2.9.1 Mexico Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.2.9.2 Mexico Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.2.9.3 Mexico Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.2.9.4 Mexico Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3 Europe
11.3.1 Trend Analysis
11.3.2 Europe Peptide Antibiotics Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.3.3 Europe Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.3.4 Europe Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.3.5 Europe Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.3.6 Europe Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.7 Germany
11.3.7.1 Germany Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.3.7.2 Germany Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.3.7.3 Germany Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.3.7.4 Germany Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.8 France
11.3.8.1 France Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.3.8.2 France Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.3.8.3 France Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.3.8.4 France Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.9 UK
11.3.9.1 UK Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.3.9.2 UK Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.3.9.3 UK Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.3.9.4 UK Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.10 Italy
11.3.10.1 ItalyPeptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.3.10.2 Italy Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.3.10.3 Italy Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.3.10.4 Italy Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.11 Spain
11.3.11.1 Spain Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.3.11.2 Spain Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.3.11.3 Spain Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.3.11.4 Spain Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.12 Poland
11.3.12.1 Poland Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.3.12.2 Poland Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.3.12.3 Poland Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.3.12.4 Poland Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.13 Turkey
11.3.13.1 Turkey Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.3.13.2 Turkey Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.3.13.3 Turkey Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.3.13.4 Turkey Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.14 Rest of Europe
11.3.14.1 Rest of Europe Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.3.14.2 Rest of Europe Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.3.14.3 Rest of Europe Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.3.14.4 Rest of Europe Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4 Asia Pacific
11.4.1 Trend Analysis
11.4.2 Asia Pacific Peptide Antibiotics Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.4.3 Asia Pacific Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.4.4 Asia Pacific Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.4.5 Asia Pacific Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.4.6 Asia Pacific Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.7 China
11.4.7.1 China Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.4.7.2 China Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.4.7.3 China Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.4.7.4 China Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.8 India
11.4.8.1 India Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.4.8.2 India Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.4.8.3 India Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.4.8.4 India Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.9 Japan
11.4.9.1 Japan Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.4.9.2 Japan Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.4.9.3 Japan Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.4.9.4 Japan Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.10 South Korea
11.4.10.1 South Korea Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.4.10.2 South Korea Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.4.10.3 South Korea Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.4.10.4 South Korea Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.11 Singapore
11.4.11.1 Singapore Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.4.11.2 Singapore Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.4.11.3 Singapore Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.4.11.4 Singapore Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.12 Australia
11.4.12.1 Australia Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.4.12.2 Australia Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.4.12.3 Australia Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.4.12.4 Australia Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.13 Rest of Asia Pacific
11.4.13.1 Rest of Asia Pacific Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.4.13.2 Rest of Asia Pacific Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.4.13.3 Rest of Asia Pacific Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.4.13.4 Rest of Asia Pacific Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5 Middle East and Africa
11.5.1 Trend Analysis
11.5.2 Middle East and Africa Peptide Antibiotics Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.5.3 Middle East and Africa Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.5.4 Middle East and Africa Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.5.5 Middle East and Africa Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.5.6 Middle East and Africa Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.7 UAE
11.5.7.1 UAE Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.5.7.2 UAE Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.5.7.3 UAE Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.5.7.4 UAE Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.8 Saudi Arabia
11.5.8.1 Saudi Arabia Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.5.8.2 Saudi Arabia Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.5.8.3 Saudi Arabia Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.5.8.4 Saudi Arabia Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.1.9 Qatar
11.5.9.1 Qatar Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.5.9.2 Qatar Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.5.9.3 Qatar Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.5.1.9.4 Qatar Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.10 South Africa
11.5.10.1 South Africa Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.5.10.2 South Africa Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.5.10.3 South Africa Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.5.10.4 South Africa Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.11 Rest of Middle East & Africa
11.5.11.1 Rest of Middle East & Africa Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.5.11.2 Rest of Middle East & Africa Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.5.11.3 Rest of Middle East & Africa Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.5.11.4 Rest of Middle East & Africa Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.6 Latin America
11.6.1 Trend Analysis
11.6.2 Latin America Peptide Antibiotics Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.6.3 Latin America Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.6.4 Latin America Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.6.5 Latin America Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.6.6 Latin America Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.6.7 Brazil
11.6.7.1 Brazil Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.6.7.2 Brazil Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.6.7.3 Brazil Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.6.7.4 Brazil Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.6.8 Argentina
11.6.8.1 Argentina Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.6.8.2 Argentina Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.6.8.3 Argentina Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.6.8.4 Argentina Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.6.9 Rest of Latin America
11.6.9.1 Rest of Latin America Peptide Antibiotics Market Estimates and Forecasts by Product (2020-2032) (USD Billion)
11.6.9.2 Rest of Latin America Peptide Antibiotics Market Estimates and Forecasts By Disease (2020-2032) (USD Billion)
11.6.9.3 Rest of Latin America Peptide Antibiotics Market Estimates and Forecasts by Route of Administration (2020-2032) (USD Billion)
11.6.9.4 Rest of Latin America Peptide Antibiotics Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
12. Company Profiles
12.1 Novo Nordisk A/S
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Pfizer Inc.,
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Teva Pharmaceutical Industries Ltd.
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Bachem Holding AG.
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Sandoz
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Ipsen S.A.,
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Merrion Pharmaceuticals
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Taiwan Liposome Company
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 PolyPeptide Group.
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Melinta Therapeutics
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
13. Use Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Product
Ribosomally Synthesized Peptide Antibiotics
Non-ribosomal Synthesized Peptide Antibiotics
By Disease
Skin Infection
HABP/VABP
Blood Stream Infections
Others
By Route of Administration
Oral
Injectable
Topical
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
